View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 16, 2019

Previously approved IDH2 inhibitor seeks label expansion in acute myeloid leukaemia

The Celgene trial was the first to demonstrate a benefit in the front-line setting for patients who are ineligible for intensive chemotherapy. 

By GlobalData Healthcare

The first interim results from Celgene’s open-label, randomised Phase II (NCT02677922) study were announced at the 2019 annual American Society of Hematology (ASH) conference on 7–10 December in Orlando, Florida, US.

The findings showed that the addition of the isocitrate dehydrogenase 2 (IDH2) inhibitor Celgene/Agios Pharmaceutical’s Idhifa (enasidenib) to low-intensity chemotherapy can benefit patients with acute myeloid leukaemia (AML) harbouring mutations in the IDH2 gene. 

Idhifa is FDA-approved for the treatment of patients with IDH2 mutations in the relapsed/refractory setting (R/R). This trial was the first to demonstrate a benefit in the front-line setting for patients who are ineligible for intensive chemotherapy. 

The addition of Idhifa to the hypomethylating agent azacitidine led to complete remission (CR) or complete remission with incomplete recovery (CRi) in 59% of patients compared to 24% of patients in the azacitidine monotherapy arm. 

The adverse effects were similar in both arms, and the safety profile of the combinatorial regimen was consistent with the safety profile of each agent alone. While premature, these data suggest that Idhifa is another option in the low-intensity induction setting, offering more options for IDH2-mutant patients.

As Idhifa is already approved for R/R patients, combined with its current off-label use in the front-line setting, this could expedite a label expansion for use in the newly-diagnosed setting. This would mean that Idhifa could be available for an additional 2,000 newly-diagnosed AML patients in the US every year. 

However, while these data may offer enough backing for Agios to submit a New Drug Application, the recent approval of AbbVie/Genentech’s Venclexta (venetoclax tablets) in the same setting will provide competition. In 2018, Venclexta gained accelerated FDA approval based on an aggregate 67% CR+CRi response rate in combination with azacitidine or decitabine in the same patient population. 

Venetoclax is well tolerated and has been widely adopted by physicians, suggesting that Idhifa, if approved, will share a piece of this market with Venetoclax. As such, it remains to be seen whether oncologists will opt to use the targeted therapy approach of Idhifa upfront or follow the established path of using Venclexta first and then switch to Idhifa on relapse. Results from the upcoming Phase III trials will shed more light on the optimal treatment sequence.

While the front-line setting of young/fit AML patients is dominated by chemotherapy regimens, the unfit and R/R patient market has seen a significant rise in branded therapies since 2017. Due to label expansion efforts and new agents entering the market, GlobalData estimates that the value of this market will increase significantly over the next five years. 

Related Reports

GlobalData (2017) Acute Myeloid Leukemia (AML) – Dynamic Market Forecast to 2026, December 2017, GDHC002FS

GlobalData (2017) EpiCast Report: Acute Myeloid Leukemia – Epidemiology Forecast to 2026, June 2017, GDHCER153-17

GlobalData (2017) OpportunityAnalyzer: Acute Myeloid Leukemia – Opportunity Analysis and Forecasts to 2026, June 2017, GDHC074POA

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena